This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Ophthalmology Podcasts

The Macular Minute Episode 13

with All Speakers

The Macular Minute Banner

Bonus Episode with All Speakers

In this 3-minute episode, we are joined by all our speakers for two quick fire questions. What is the biggest challenge facing medical retina clinics? And how would you describe the impact EYLEA® (aflibercept) 8 mg has had on your patients?

 

This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.

Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.

Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.

Speakers & Disclosures

Richard Gale

Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust

Speaker Disclosures: Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen, Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen

 

Rossella Anzidei

Consultant Ophthalmologist at University Hospitals Leicester NHS Trust

Speaker Disclosures: Speaker and travel grants: AbbVie, Bayer and Novartis

 

Sobha Sivaprasad

Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust

Speaker Disclosures: Financial support from AbbVie, Amgen, Apellis Pharmaceuticals, Bayer, Biogen, Boehringer Ingelheim, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi and Stealth BioTherapeutics

 

Hani Hasan

Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust

Speaker Disclosures: Speaker and travel grants: AbbVie, Bayer and Roche

 

Bhavin Maru

Lead Nurse in Ophthalmology at Imperial College Healthcare NHS Trust

Speaker Disclosures: Speaker fees and travel support from Bayer

 

Serena Salvatore

Consultant Ophthalmologist at University Hospitals Bristol and Weston NHS Foundation Trust

Speaker Disclosures: Advisory board and speaker fees: Bayer, Roche. Travel bursary and speaker fees: Alimera sciences

References

  1. EYLEA® 40 mg/mL Summary of Product Characteristics.
  2. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2321, September 2024
The Macular Minute: Podcast Series
Your source for quick expert insights in medical retina
PP-EYL-GB-2538, January 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2553 | December 2024